3-chloro-4-ethyl-6-phenylpyridazine | 28657-44-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 3-chloro-4-ethyl-6-phenylpyridazine
• CAS: 28657-44-5
• 化学式: C₁₂H₁₁ClN₂
• 分子量: 218.686
• InChiKey: KLMPJMBHVVJRJT-UHFFFAOYSA-N

物化性质

• 沸点：
  379.1±37.0 °C(Predicted)
• 密度：
  1.176±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-chloro-4-ethyl-6-phenylpyridazine 在 palladium on activated charcoal ammonium hydroxide 、 氢气 作用下， 以 乙醇 为溶剂， 反应 0.5h， 以94%的产率得到5-ethyl-3-phenylpyridazine
  参考文献：
  名称：

  Samaritoni, Jack G.; Babbitt, George, Journal of Heterocyclic Chemistry, 1991, vol. 28, # 3, p. 583 - 587

  摘要：

  DOI：
• 作为产物：
  描述：

  3-氯-6-苯基哒嗪 、 丙酸 在 ammonium peroxydisulfate 、 硫酸 、 silver nitrate 作用下， 以 水 、 乙腈 为溶剂， 反应 0.5h， 以17%的产率得到3-chloro-4-ethyl-6-phenylpyridazine
  参考文献：
  名称：

  Samaritoni, Jack G.; Babbitt, George, Journal of Heterocyclic Chemistry, 1991, vol. 28, # 3, p. 583 - 587

  摘要：

  DOI：

文献信息

• [EN] AURORA KINASE MODULATORS AND METHOD OF USE<br/>[FR] MODULATEURS D'AURORA KINASE ET PROCÉDÉ D'UTILISATION
  申请人：AMGEN INC

  公开号：WO2009117157A1

  公开（公告）日：2009-09-24

  The present invention relates to chemical compounds having a general formula (I) wherein A1-5 and 7-8, D', L1, L2, R1, R3, R6-8, n and o are defined herein, and synthetic intermediates, which are capable of modulating the activity of Aurora kinase proteins and, thereby, influencing various disease states and conditions related to the activities of Aurora kinases. For example, the compounds are capable of influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.

  本发明涉及具有一般式(I)的化合物，其中在此定义了A1-5和7-8，D'，L1，L2，R1，R3，R6-8，n和o，以及合成中间体，这些化合物能够调节枢纽激酶蛋白的活性，从而影响与枢纽激酶活动相关的各种疾病状态和病况。例如，这些化合物能够影响细胞周期和细胞增殖过程，以治疗癌症和与癌症相关的疾病。该发明还包括包括这些化合物的药物组合物，以及治疗与枢纽激酶活性相关的疾病状态的方法。
• Aurora Kinase Modulators and Method of Use
  申请人：Amgen Inc.

  公开号：US20140336182A1

  公开（公告）日：2014-11-13

  The present invention relates to chemical compounds having a general formula I wherein A 1-8 , D′, L 1 , L 2 , R 1 , R 6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.

  本发明涉及具有一般式I的化合物，其中A1-8、D'、L1、L2、R1、R6-8和n在此处定义，并且具有调节各种蛋白激酶受体酶并因此影响与这些激酶活动相关的各种疾病状态和病况的能力的合成中间体。例如，这些化合物能够调节枢纽激酶，从而影响细胞周期和细胞增殖过程，以治疗癌症和与癌症相关的疾病。该发明还包括包括这些化合物的药物组合物，以及治疗与枢纽激酶活性相关的疾病状态的方法。
• Aurora kinase modulators and method of use
  申请人：Cee J. Victor

  公开号：US20070185111A1

  公开（公告）日：2007-08-09

  The present invention relates to chemical compounds having a general formula I wherein A 1 , A 2 , C 1 , C 2 , D, L 1 , L 2 , Z and R 1 - are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.

  本发明涉及具有一般式I的化合物，其中A1、A2、C1、C2、D、L1、L2、Z和R1-在此定义，并且具有调节各种蛋白激酶受体酶的能力，从而影响与这些激酶活动相关的各种疾病状态和病况。例如，这些化合物能够调节枢纽激酶，从而影响细胞周期和细胞增殖过程，用于治疗癌症和癌症相关疾病。该发明还包括含有这些化合物的药物组合物，以及治疗与枢纽激酶活性相关的疾病状态的方法。
• Pyridazine Compounds, Compositions and Methods
  申请人：Watterson Martin

  公开号：US20080318899A1

  公开（公告）日：2008-12-25

  The invention relates to novel chemical compounds and methods of making and using the same. In particular, the invention provides pyridazine compounds and/or related heterocyclic derivatives, compositions comprising the same, and methods of using pyridazine compounds and/or related heterocyclic derivatives and compositions comprising the same, for modulation of cellular pathways (e.g., signal transduction pathways), for treatment or prevention of inflammatory diseases (e.g., Alzheimer's disease), for research, drug screening, and therapeutic applications.

  本发明涉及新型化合物和制备和使用它们的方法。具体而言，本发明提供吡嗪化合物和/或相关的杂环衍生物，包括这些化合物的组合物，以及使用吡嗪化合物和/或相关的杂环衍生物和组合物的方法，用于调节细胞通路（例如信号转导通路），用于治疗或预防炎症性疾病（例如阿尔茨海默病），用于研究、药物筛选和治疗应用。
• AURORA KINASE MODULATORS AND METHOD OF USE
  申请人：Deak Holly

  公开号：US20100280008A1

  公开（公告）日：2010-11-04

  The present invention relates to chemical compounds having a general formula I wherein A 1-8 , D′, L 1 , L 2 , R 1 , R 6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.

  本发明涉及具有一般式I的化合物，其中A1-8、D'、L1、L2、R1、R6-8和n在此定义，并且合成中间体能够调节各种蛋白激酶受体酶，从而影响与这些激酶活动相关的各种疾病状态和条件。例如，这些化合物能够调节极化分裂激酶，从而影响细胞周期和细胞增殖的过程，以治疗癌症和与癌症相关的疾病。该发明还包括包括这些化合物的药物组合物以及治疗与极化分裂激酶活性相关的疾病状态的方法。